CN101541806A - 用作血管升压素拮抗剂的螺环苯并氮杂 - Google Patents

用作血管升压素拮抗剂的螺环苯并氮杂 Download PDF

Info

Publication number
CN101541806A
CN101541806A CNA2007800432003A CN200780043200A CN101541806A CN 101541806 A CN101541806 A CN 101541806A CN A2007800432003 A CNA2007800432003 A CN A2007800432003A CN 200780043200 A CN200780043200 A CN 200780043200A CN 101541806 A CN101541806 A CN 101541806A
Authority
CN
China
Prior art keywords
compound
phenyl
carbonyl
dihydro
spiro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007800432003A
Other languages
English (en)
Chinese (zh)
Inventor
M·A·向
M·帕特尔
P·赖布琴斯基
J·冈内特
K·T·德马雷斯特
R·卢克
B·马里亚诺夫
M·J·科斯坦佐
S·C·亚布特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of CN101541806A publication Critical patent/CN101541806A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CNA2007800432003A 2006-09-22 2007-09-19 用作血管升压素拮抗剂的螺环苯并氮杂 Pending CN101541806A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82665406P 2006-09-22 2006-09-22
US60/826,654 2006-09-22

Publications (1)

Publication Number Publication Date
CN101541806A true CN101541806A (zh) 2009-09-23

Family

ID=39030853

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2007800432003A Pending CN101541806A (zh) 2006-09-22 2007-09-19 用作血管升压素拮抗剂的螺环苯并氮杂

Country Status (14)

Country Link
US (1) US7825110B2 (https=)
EP (1) EP2078022B1 (https=)
JP (1) JP2010504351A (https=)
CN (1) CN101541806A (https=)
AT (1) ATE532786T1 (https=)
AU (1) AU2007299818B2 (https=)
CA (1) CA2665849A1 (https=)
CY (1) CY1112270T1 (https=)
DK (1) DK2078022T3 (https=)
ES (1) ES2374582T3 (https=)
PL (1) PL2078022T3 (https=)
PT (1) PT2078022E (https=)
SI (1) SI2078022T1 (https=)
WO (1) WO2008036755A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112939864A (zh) * 2021-01-29 2021-06-11 中国医科大学 螺[苯并[c]氮杂-1,1’-环己基]-3-酮类化合物
WO2022111581A1 (zh) * 2020-11-26 2022-06-02 上海济煜医药科技有限公司 新型苯并氮杂卓螺环衍生物
WO2026002248A1 (zh) * 2024-06-28 2026-01-02 上海济煜医药科技股份有限公司 作为v2受体拮抗剂的苯并氮杂卓并环衍生物

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8921576B2 (en) 2011-10-19 2014-12-30 Kowa Company, Ltd. Spiroindoline compound, and medicinal agent comprising same
BR112017000762A2 (pt) 2014-07-15 2017-11-21 Gruenenthal Gmbh derivados de azaspiro(4.5)decano substituído.
TW201607923A (zh) 2014-07-15 2016-03-01 歌林達有限公司 被取代之氮螺環（４．５）癸烷衍生物
HK1251223A1 (en) 2015-07-07 2019-01-25 Japan Tobacco, Inc. Method for producing 7h-pyrrolo[2, 3-d]pyrimidine derivative and intermediate thereof
AU2017384317C1 (en) 2016-12-21 2022-06-30 Japan Tobacco Inc. PROCESS FOR PREPARING 7H-PYRROLO[2,3-d]PYRIMIDINE DERIVATIVES AND SYNTHETIC INTERMEDIATES THEREOF
WO2019055913A1 (en) * 2017-09-15 2019-03-21 Azevan Pharmaceuticals, Inc. COMPOSITIONS AND METHODS FOR TREATMENT OF BRAIN INJURY
WO2019141575A1 (de) 2018-01-16 2019-07-25 Bayer Aktiengesellschaft Unterstützung bei der behandlung von herzinsuffizienz
WO2022032073A2 (en) * 2020-08-07 2022-02-10 Casma Therapeutics, Inc. Trpml modulators
EP4491699A1 (de) 2023-07-13 2025-01-15 Klueber Lubrication München GmbH & Co. KG Phthalimidverbindungen als basisöl für schmierstoffzusammensetzungen

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4617302A (en) * 1984-10-15 1986-10-14 Eli Lilly And Company Inotropic agents
DK0450097T3 (da) * 1989-10-20 1996-05-20 Otsuka Pharma Co Ltd Benzoheterocykliske forbindelser
US5258510A (en) * 1989-10-20 1993-11-02 Otsuka Pharma Co Ltd Benzoheterocyclic compounds
US5985869A (en) * 1989-10-20 1999-11-16 Otsuka Pharmaceutical Company, Limited Benzoheterocyclic compounds
JP2905909B2 (ja) * 1991-04-19 1999-06-14 大塚製薬株式会社 バソプレシン拮抗剤
FR2686878B1 (fr) * 1992-01-30 1995-06-30 Sanofi Elf Derives du n-sulfonyl oxo-2 indole, leur preparation, les compositions pharmaceutiques en contenant.
US5686624A (en) * 1992-01-30 1997-11-11 Sanofi 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
US5663431A (en) * 1992-01-30 1997-09-02 Sanofi 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
FR2708605A1 (fr) * 1993-07-30 1995-02-10 Sanofi Sa Dérivés du N-sulfonylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant.
US5849780A (en) * 1992-01-30 1998-12-15 Sanofi 1-benzenesulfonyl-1-1,3-dihydroindol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
JPH08502474A (ja) 1992-10-07 1996-03-19 メルク エンド カンパニー インコーポレーテッド トコリティックオキシトシンレセプターアンタゴニスト
US5512563A (en) 1993-07-29 1996-04-30 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
FR2708606B1 (fr) * 1993-07-30 1995-10-27 Sanofi Sa Dérivés du N-phénylalkylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant.
US5464788A (en) 1994-03-24 1995-11-07 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
US5753648A (en) 1995-01-17 1998-05-19 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
AUPP150098A0 (en) 1998-01-27 1998-02-19 Fujisawa Pharmaceutical Co., Ltd. Benzamide derivatives
WO2002002531A1 (en) 2000-07-05 2002-01-10 Ortho-Mcneil Pharmaceutical, Inc. Nonpeptide substituted spirobenzoazepines as vasopressin antagonists
AU2002231098A1 (en) * 2000-12-15 2002-06-24 Emory University Nonpeptide agonists and antagonists of vasopressin receptors
US7011898B2 (en) * 2003-03-21 2006-03-14 Air Products And Chemicals, Inc. Method of joining ITM materials using a partially or fully-transient liquid phase
AR044782A1 (es) * 2003-06-17 2005-10-05 Ortho Pharma Corp Espirobenzazepinas sustituidas utiles como antagonistas de los receptores de vasopresina
EP1633721A1 (en) * 2003-06-17 2006-03-15 Janssen Pharmaceutica N.V. Process for the preparation of nonpeptide substituted spirobenzoazepine derivatives
WO2007084591A2 (en) * 2006-01-20 2007-07-26 Janssen Pharmaceutica N.V. Novel solid forms of (4r)-1-[4-(2-chloro-5-fluorobenzoyl)amino-3-methoxybenzoyl]-1,2,3,5-tetrahydro-spiro[4h-1-benzazepine-4,1'-[2]cyclopentene]-3'-carboxylic acid

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022111581A1 (zh) * 2020-11-26 2022-06-02 上海济煜医药科技有限公司 新型苯并氮杂卓螺环衍生物
CN116472271A (zh) * 2020-11-26 2023-07-21 上海济煜医药科技有限公司 新型苯并氮杂卓螺环衍生物
TWI831088B (zh) * 2020-11-26 2024-02-01 大陸商上海濟煜醫藥科技有限公司 新型苯并氮雜卓螺環衍生物
CN116472271B (zh) * 2020-11-26 2025-09-23 上海济煜医药科技股份有限公司 新型苯并氮杂卓螺环衍生物
CN112939864A (zh) * 2021-01-29 2021-06-11 中国医科大学 螺[苯并[c]氮杂-1,1’-环己基]-3-酮类化合物
WO2026002248A1 (zh) * 2024-06-28 2026-01-02 上海济煜医药科技股份有限公司 作为v2受体拮抗剂的苯并氮杂卓并环衍生物

Also Published As

Publication number Publication date
ES2374582T3 (es) 2012-02-20
WO2008036755A1 (en) 2008-03-27
EP2078022A1 (en) 2009-07-15
PL2078022T3 (pl) 2012-04-30
CA2665849A1 (en) 2008-03-27
US7825110B2 (en) 2010-11-02
DK2078022T3 (da) 2012-02-13
ATE532786T1 (de) 2011-11-15
AU2007299818B2 (en) 2012-08-02
AU2007299818A1 (en) 2008-03-27
EP2078022B1 (en) 2011-11-09
PT2078022E (pt) 2012-01-11
JP2010504351A (ja) 2010-02-12
US20080076753A1 (en) 2008-03-27
SI2078022T1 (sl) 2012-01-31
CY1112270T1 (el) 2015-12-09

Similar Documents

Publication Publication Date Title
CN101541806A (zh) 用作血管升压素拮抗剂的螺环苯并氮杂
CN101541807A (zh) 用作血管升压素拮抗剂的螺环苯并氮杂
TWI642667B (zh) 吡啶並嘧啶類衍生物、其製備方法及其在醫藥上的應用
WO2023072297A1 (zh) 含氮的四环化合物、其制备方法及其在医药上的应用
WO2014127350A1 (en) Modulators of vasopressin receptors with therapeutic potential
WO1998011128A1 (de) Abgewandelte aminosäuren, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
JP2015529252A (ja) フルオロアルキル−１，４−ベンゾジアゼピノン化合物
KR20220079546A (ko) 간질 치료 방법
TWI826406B (zh) 作為血管升壓素Ｖ１ａ受體拮抗劑之三唑並苯並吖呯
CN103068800A (zh) 作为趋化因子受体活性调节剂的哌啶基化合物
CN102209718A (zh) 氨基甲酸酯化合物或其盐
ES2893824T3 (es) Derivados de pirazolo[1,5-a]pirimidina con sustitución alicíclica farmacológicamente activos
WO2019158070A1 (zh) A2a和/或a2b受体拮抗剂
JP2007538084A (ja) チエノピリジノン化合物及び治療方法
JP2002053566A (ja) チアゾール化合物及びその医薬用途
CN103429588A (zh) 晶态噁嗪衍生物及其作为bace抑制剂的用途
EP3412664B1 (en) Heterocyclic sulfonamide derivative and medicine containing same
EP2751095B1 (en) Novel benzodiazepinones as modulators of metabotropic glutamate receptor functions and neurological uses thereof
JP2011201777A (ja) 光学活性なヘテロシクリデン−ｎ−アリールアセトアミド誘導体
CN112592354B (zh) 一种异噁唑并嘧啶类杂环化合物的制备方法
US20170313686A1 (en) Compounds and their use as bace inhibitors
CN104774188A (zh) 苯并杂环类或苯并杂芳环类衍生物、其制备方法及其在医药上的应用
CA2723623C (en) Therapeutic agent for pain
JP2011201776A (ja) ヘテロシクリデン−ｎ−（３，４−ジヒドロ−２（１ｈ）−キナゾリノン−５−イル）アセトアミド誘導体
US20130203789A1 (en) Novel Inhibitors of LYN Kinase and Methods Using Same

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20090923